Medicare Prior Authorization: How It Works in 2026

Medicare covers prescription drugs and medical services for tens of millions of Americans, but coverage does not always mean instant access. Medicare prior authorization requires your doctor to get advance approval from your plan before it will pay for certain medications, procedures, or services. A widely cited report from the HHS Office of Inspector General found that Medicare Advantage plans denied a large number of prior authorization requests annually – and that a significant share of those denials were later overturned on appeal. Knowing the rules, timelines, and appeal options puts you in a stronger position. This article is general information, not medical, legal, or insurance advice; verify current rules at Medicare.gov or with your plan.

What Medicare Prior Authorization Covers

Prior authorization in Medicare applies differently across the parts of the program, each with its own rules:

Medicare Part D (prescription drugs): Your Part D plan – administered by a pharmacy benefit manager like Express Scripts, CVS Caremark, or OptumRx – may require prior authorization for certain covered drugs. This is the most common type of Medicare prior authorization for beneficiaries.

Medicare Advantage (Part C): Private insurance companies that offer Medicare Advantage plans can require prior authorization for medical services, procedures, specialist visits, and Part B drugs (medications administered in a clinical setting). Medicare Advantage plans have historically used prior authorization far more aggressively than Original Medicare, and PA is one of the main utilization-management tools these plans rely on.

Original Medicare (Parts A and B): Original Medicare has historically required prior authorization for only a narrow set of items – including certain repetitive scheduled non-emergent ambulance transport, some durable medical equipment, and a limited list of outpatient department services – where waste or abuse has been documented. That narrow footprint is beginning to change under a new CMS pilot, the WISeR Model, described below.

How Medicare Part D Prior Authorization Works

When your Part D plan requires prior authorization for a medication, the process follows CMS-regulated timelines:

Standard request: Your doctor submits clinical documentation to the plan (a coverage determination request). For a standard Part D request, the plan must generally notify you of its decision within 72 hours. If additional information is needed, the plan contacts your prescriber.

Expedited (urgent) request: If your doctor certifies that waiting the standard timeframe could seriously jeopardize your health, the plan must respond within 24 hours. This expedited timeline applies when you are currently in the hospital, starting a new treatment for a serious condition, or when the medication is needed to prevent significant harm.

Transition supply: If you are new to a Part D plan – at the beginning of the year, when switching plans, or when transitioning from a hospital – the plan must provide a temporary supply of your current medications (typically at least a 30-day supply) while prior authorization is processed. This transition fill helps ensure you do not go without medication during the administrative process.

CMS Rule Changes Affecting Prior Authorization (2026-2027)

The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), finalized in early 2024, introduces changes that phase in over 2026 and 2027 for Medicare Advantage, Medicaid, CHIP, and qualified health plan issuers:

Faster decision timelines (starting 2026): The rule requires affected payers to decide expedited (urgent) requests within 72 hours and standard requests within 7 calendar days. For Medicare Advantage, the 7-day standard timeframe is a tightening from the prior standard. These operational requirements begin January 1, 2026.

Denial transparency (starting 2026): Plans must include a specific reason for any prior authorization denial, citing the criteria that were not met. This replaces vague denial language with actionable information that helps providers craft targeted appeals.

Prior authorization metrics (first reports in 2026): Plans must publicly report prior authorization approval rates, denial rates, and average decision times, with the first metrics generally due by March 31, 2026. This transparency lets beneficiaries weigh a plan’s PA practices during open enrollment.

Electronic prior authorization APIs (starting 2027): By January 1, 2027, affected payers must implement standardized Health Level 7 (HL7) FHIR-based APIs – including a Prior Authorization API – alongside Patient Access, Provider Access, and Payer-to-Payer APIs. These enable near-real-time processing of PA requests through provider electronic health records. Note the split timeline: the process rules land in 2026, but the technology (API) requirements take effect in 2027.

The WISeR Model: Prior Authorization Comes to Original Medicare

A significant development is the CMS Innovation Center’s WISeR Model (Wasteful and Inappropriate Service Reduction), which for the first time pilots prior-authorization-style review inside Original (Traditional) Medicare. According to CMS, the model tests using enhanced technology – including artificial intelligence and machine learning – combined with human clinical review to reduce spending on services CMS considers potentially wasteful or low-value.

Key facts to know about WISeR:

Timeline: The model runs across six performance years, from January 1, 2026 through December 31, 2031.

Selected services only: WISeR focuses on a short list of items and services – skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for knee osteoarthritis. It does not apply to emergency services or inpatient-only procedures.

Six states: The model operates in New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington.

Who is affected: WISeR applies to people with Original Medicare who receive one of the selected services in a participating state. CMS has stated the model does not apply to people enrolled in Medicare Advantage and will have no impact on them. Providers can submit a prior authorization request or, if they choose not to participate in prior authorization, face pre-payment medical review before the claim is paid.

Because WISeR is a time-limited pilot and its scope may evolve, confirm whether it affects a specific planned service at Medicare.gov or with your provider.

Common Medications Requiring Medicare Prior Authorization

Not every Medicare-covered drug requires prior authorization. The medications most commonly subject to PA include:

GLP-1 receptor agonists: Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) frequently require PA due to high cost and specific clinical criteria. Plans typically require documentation of a diabetes or obesity-related diagnosis, failed lifestyle interventions, and specific BMI or A1C thresholds. See our Medicare Wegovy coverage guide for details.

Specialty biologics: Medications for rheumatoid arthritis, psoriasis, multiple sclerosis, and cancer almost always require PA under Part D or Part B. Plans want documentation of diagnosis, prior treatment failures, and monitoring plans.

Controlled substances: Opioids above certain quantity thresholds, benzodiazepines, and other controlled substances may require PA, particularly under CMS’s opioid safety policies.

High-cost brand-name drugs with generic alternatives: When a generic equivalent is available, many Part D plans require PA before covering the brand-name version.

How to Appeal a Medicare Prior Authorization Denial

Medicare provides a structured, multi-level appeals process. Each level adds an independent layer of review. (The steps below describe the Part D drug appeals path; Medicare Advantage and Original Medicare appeals follow parallel multi-level processes with their own forms and deadlines.)

Level 1 – Plan redetermination: Request a redetermination from your Part D plan within 60 days of the denial. The plan must decide within 7 days (standard) or 72 hours (expedited). Submit additional clinical documentation with the appeal.

Level 2 – Independent Review Entity (IRE): If the plan upholds the denial, you can appeal to an IRE within 60 days. The IRE is an independent organization contracted by CMS. Decision timeline: 7 days standard, 72 hours expedited.

Level 3 – Office of Medicare Hearings and Appeals (OMHA): For claims meeting a minimum dollar threshold (a figure CMS adjusts annually – roughly in the low $200s in recent years, so verify the current amount), you can request a hearing before an Administrative Law Judge within 60 days of the IRE decision.

Levels 4 and 5: Further appeals go to the Medicare Appeals Council and, ultimately, to federal court. These levels are rarely needed for prescription drug PA disputes but are available.

According to CMS and independent analyses, a meaningful percentage of Part D and Medicare Advantage denials are overturned at the plan or IRE level. The key is submitting comprehensive clinical documentation that directly addresses the plan’s coverage criteria.

Medicare Advantage vs. Original Medicare: PA Differences

Medicare Advantage plans have significantly broader authority to use prior authorization than Original Medicare. This is a critical distinction for beneficiaries choosing between the two.

Under Original Medicare, PA has traditionally been required for only a narrow set of items and services (with the WISeR pilot now adding a few more in select states). Your doctor orders a test or prescribes a medication, and Medicare typically pays its share without pre-approval. This relative simplicity is one of Original Medicare’s selling points.

Medicare Advantage plans, run by private insurers, can require PA for a wide range of covered services – hospital admissions, imaging, specialist referrals, outpatient procedures, and Part B drugs. The HHS OIG and KFF have documented that some Medicare Advantage plans imposed PA requirements that delayed or denied care that Original Medicare would have covered. CMS has responded with stricter oversight, coverage-parity rules, and the new transparency and timeline requirements phasing in during 2026 and 2027.

Frequently Asked Questions

Does Medicare Part B require prior authorization?

Original Medicare Part B requires prior authorization for a limited set of services, including certain durable medical equipment, repetitive ambulance transport, some outpatient department procedures, and – under the WISeR pilot in six states – a few additional services. Medicare Advantage plans may require PA for a much broader range of Part B services, including physician-administered drugs.

Does the WISeR Model affect me if I have Medicare Advantage?

No. CMS states the WISeR Model applies only to Original Medicare beneficiaries receiving selected services in the six participating states (New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington). It does not apply to Medicare Advantage enrollees.

How long is a Medicare prior authorization valid?

Approval duration varies by plan and medication. Most Part D prior authorizations are valid for up to 12 months, after which a renewal request is required. Some medications, particularly controlled substances, may have shorter approval periods of 3 to 6 months.

Can my pharmacy give me an emergency supply while prior authorization is pending?

Yes. Part D plans are required to provide a temporary transition supply when you are new to a plan or when a PA is pending for a current medication. This supply is typically 30 days. Your pharmacist can process this as a transition fill. You may still owe a copay for the temporary supply.

What if my Medicare Advantage plan denies a prior authorization that Original Medicare would cover?

Medicare Advantage plans must cover everything Original Medicare covers, but they can apply utilization-management tools like prior authorization. If you believe a denial is improper, appeal through the plan’s process and cite CMS rules requiring coverage parity with Original Medicare. The independent review at Level 2 is particularly important for these disputes.

Protecting Your Medicare Benefits

Medicare prior authorization does not have to be an obstacle if you approach it strategically. Have your doctor check PA requirements before prescribing or ordering a service. Ensure the clinical documentation is complete and specific from the first submission. Know the timelines – 72 hours for standard Part D requests, 24 hours for urgent, and 7 calendar days for standard Medicare Advantage decisions under the 2026 rule – and hold the plan accountable if it misses them. And when a denial happens, appeal promptly with additional evidence.

For a deeper look at how PBM reform is reshaping Medicare pharmacy benefits, and how prior authorization connects to the broader policy landscape, explore our healthcare policy guide.

Sources

• CMS – Interoperability and Prior Authorization Final Rule (CMS-0057-F) fact sheet (decision-timeline, denial-transparency, and metrics requirements beginning 2026; FHIR API requirements effective January 1, 2027)
• CMS Innovation Center – WISeR Model (Wasteful and Inappropriate Service Reduction): selected services, six states, performance years January 1, 2026-December 31, 2031; does not apply to Medicare Advantage
• Medicare.gov – coverage determinations, transition supply, and the five-level appeals process
• HHS Office of Inspector General – reports on Medicare Advantage prior authorization denials and overturn rates
• KFF (Kaiser Family Foundation) – analyses of prior authorization in Medicare Advantage